MedTrace Logo

OCS-05 in Patients With Optic Neuritis

NCT04762017 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2025-09-22

No results posted yet for this study

Summary

To evaluate the safety and tolerability of OCS-05 compared to placebo in patients with optic neuritis receiving the standard of care

Conditions

Interventions

DRUG

OCS-05 +SoC (corticosteroid) IV administration

OCS-05 + SoC (corticosteroid) IV administration for 5 consecutive days

OTHER

Placebo + SoC (corticosteroid) IV administration

Placebo + SoC (corticosteroid) IV administration for 5 consecutive days

Sponsors & Collaborators

  • Neurotrials

    collaborator UNKNOWN

  • Oculis

    lead INDUSTRY

Principal Investigators

  • Sharon Klier, MD, MPH · Oculis

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-10
Primary Completion
2024-09-16
Completion
2024-09-16

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04762017 on ClinicalTrials.gov